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The neuronal glutamate transporter gene SLC1A1 is a candidate
gene for obsessive-compulsive disorder (OCD) based on linkage
studies and convergent evidence implicating glutamate in OCD
etiology. The 30 end of SLC1A1 is the only genomic region with
consistently demonstrated OCD association, especially when
analyzing male-only probands. However, speciﬁc allele associ-
ations have not been consistently replicated, and recent OCD
genome-wide association and meta-analysis studies have not
incorporated all previously associated SLC1A1 SNPs. To clarify
the nature of association between SLC1A1 and OCD, pooled
analysis was performed on all available relevant raw study data,
comprising aﬁnal sample of 815 trios, 306 cases and 634 controls.
This revealed weak association between OCD and one of
nine tested SLC1A1 polymorphisms (rs301443; uncorrected
P¼ 0.046; non-signiﬁcant corrected P). Secondary analyses of
male-affecteds only (N¼ 358 trios and 133 cases) demonstrated
modest association between OCD and a different SNP
(rs12682807; uncorrected P¼ 0.012; non-signiﬁcant corrected
P). Findings of thismeta-analysis are consistentwith the trend of
previous candidate gene studies in psychiatry and do not clarify
the putative role of SLC1A1 in OCD pathophysiology. Nonethe-
less, it may be important to further examine the potential
associations demonstrated in this amalgamated sample, espe-
cially since the SNPswithmodest associations were not included
in the more highly powered recent GWAS or in a past meta-
analysis including ﬁve SLC1A1 polymorphisms. This study
underscores the need for much larger sample sizes in future
genetic association studies and suggests that next-generation
sequencing may be beneﬁcial in examining the potential role of
rare variants in OCD.  2013 Wiley Periodicals, Inc.
Key words: obsessive-compulsive disorder; OCD; candidate
gene; meta-analysis; SLC1A1; glutamate
INTRODUCTION
Obsessive-compulsive disorder (OCD) is a debilitating anxiety
disorder characterized by recurrent intrusive thoughts and/or
rituals intended to mitigate anxiety [American Psychiatric Associ-
ation, 2000]. OCD is a common psychiatric illness, with estimated
lifetime prevalence rates ranging from 1% to 3%worldwide [Karno
et al., 1988; Weissman et al., 1994; Kessler et al., 2005]. The genetic
architecture of OCD is thought to be complex, [Cavallini et al.,
1999; Nestadt et al., 2000a; Hanna et al., 2005a,b] but the speciﬁc
mechanisms of this etiologic contribution have not yet been
established. Despite numerous family, twin, and segregation anal-
yses indicating substantial heritability of OCD, [Inouye, 1965; van
Grootheest et al., 2005]most candidate gene ﬁndings have not been
consistently replicated [Hemmings and Stein, 2006; Grados and
Wilcox, 2007; Nestadt et al., 2010]. To date, gene selection for these
studies has been guided by pathophysiological and pharmacologi-
cal knowledge and therefore has focused primarily on the seroto-
nergic and dopaminergic systems. However, among published
OCD candidate gene studies, only those focusing on the glutamate
transporter gene SLC1A1 have demonstrated consistent evidence of
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association [Hemmings and Stein, 2006; Grados andWilcox, 2007;
Nestadt et al., 2010].
Evidence suggests that abnormal glutamatergic neurotransmis-
sion may contribute to OCD pathophysiology [Pittenger et al.,
2006, 2011; Wu et al., 2012]. Elevated glutamate concentrations
have been found in the cerebrospinal ﬂuid of OCD subjects,
[Chakrabarty et al., 2005] and magnetic resonance spectroscopy
investigations have revealed altered glutamatergic concentrations
in the orbitofrontal white matter of adult patients with OCD
[Whiteside et al., 2006] and in the anterior cingulate cortex of
both pediatric and adult OCD subjects [Rosenberg et al., 2004;
Yucel et al., 2008]. Positron emission tomography studies of OCD
have shown increased glucose metabolism and blood ﬂow in the
cortico-striatal-thalamo-cortical (CSTC) circuit [Swedo et al.,
1989; Rauch et al., 1994; Saxena and Rauch, 2000]. Moreover,
two OCD rodent model studies have implicated glutamate-related
genes, SAPAP3 and SLITRK5 [Welch et al., 2007; Mah, 2010].
Additionally, pharmacological evidence for the role of glutamater-
gic activity in OCD is emerging. Multiple studies have reported
symptom improvement in OCD by augmenting with glutamate-
modulating agents such as riluzole [Coric et al., 2005; Grant
et al., 2007] or memantine [Aboujaoude et al., 2009; Stewart
et al., 2010].
Located on chromosome 9p24, SLC1A1 encodes the neuronal
and epithelial high afﬁnity glutamate transporter EAAC1, also
called EAAT3, which is expressed in brain regions implicated in
OCD, [Menzies et al., 2008] including the cerebral cortex, striatum,
and thalamus [Kanai and Hediger, 2004]. In contrast to the other
studied glutamate-related candidate genes such asGRIK2 [Sampaio
et al., 2011] and BDNF [Nicolini et al., 2009], SLC1A1 is also a
strong positional candidate. A whole genome linkage scan on 56
individuals from sevenmultigenerationalOCD-affected families by
Hanna et al. [2002] identiﬁed a linkage peak containing the 9p24
region (LOD2.25), and a targeted replication study in this regionon
50 multiplex or sibling pair pedigrees by Willour et al. [2004b]
found suggestive evidence for linkage within 0.5 cM (<350 kb) of
the original signal (HLOD 2.26). However, a subsequent full
genome linkage scan primarily in sibling pairs did not ﬁnd evidence
for linkage in this region [Shugart et al., 2006b].Of the knowngenes
within this region, SLC1A1 is one of only two with demonstrated
expression in the brain [Smith et al., 1994].
To date, ﬁve candidate gene studies have reported associations
between OCD and multiple single nucleotide polymorphisms
(SNPs) and/or haplotypes within the 30 region of SLC1A1
[Arnold et al., 2006;Dickel et al., 2006; Stewart et al., 2007a; Shugart
et al., 2009; Wendland et al., 2009] (see Table I). A recent study by
Samuels et al. [2011] also found evidence of association with OCD
in the 50 region of SLC1A1. No negative candidate gene studies of
SLC1A1 in OCD have been published. Among the ﬁve studies
examining the 30 region of the gene, some of the analyzed SNPs
overlapped, while others were unique across studies. The majority
of SNP and haplotype associations reported in individual studies
have not been replicated in other samples, and none of the SLC1A1
polymorphisms has been conﬁrmed as a susceptibility locus for
OCD. Of the 18 SNPs analyzed from the 30 region of SLC1A1 in at
least two published studies, only rs3780412 has demonstrated
association as a single marker in more than one study sample
(after correction for multiple testing [Dickel et al., 2006; Stewart
et al., 2007a]).
Both Dickel et al. [2006] and Stewart et al. [2007a] found
evidence of association with rs3780412, although the effects
were in opposite directions. Dickel et al. [2006] reported over-
transmission while Stewart et al. [2007b] reported under-
transmission of the major allele to affected male probands.
Incidentally, Kwon et al. [2009] also found weak evidence
of support for association between this SNP and atypical
antipsychotic-induced OC symptoms (permuted P¼ 0.07).
Because the sample sizes of the ﬁve OCD 30 SLC1A1 candidate
gene studies were small (N¼ 66–378 families), and also given
the complex genetics of OCD, these ambiguous results are
not surprising. Most recently, the ﬁrst genome-wide association
study (GWAS) of OCD has been published [Stewart et al., 2012],
which did not identify signiﬁcant association with any of the four
examined SLC1A1 SNPs, including rs2072657, rs301430, rs301434,
and rs3780412. However, the GWAS notably did not examine
several SLC1A1 SNPs with previous reported association with
OCD, and sex-speciﬁc analyses were not conducted. Moreover, a
recentmeta-analysis ofOCDgenetic association studies did not use
raw genotype data to apply standard quality control thresholds
across samples, and only examined ﬁve SLC1A1 SNPs in primary
analyses [Taylor, 2012].
In order to increase the statistical power to detect association
between SLC1A1 andOCD, and to detect the potential inﬂuence of
publicationbias or issues ofmultiple testing, the authors aggregated
the raw data from the four published family-based association
studies with unpublished data from genotyping performed by the
OCD Mini-Collaborative, a subgroup of the International OCD
Genetics Collaborative, consisting of research sites in Boston, Ann
Arbor (Michigan), San Francisco, and Toronto. Analyses com-
prised an initial pooled analysis of this combined family-based
association data, followed by a meta-analysis incorporating these
results with the previously published results of a case–control
association study. Secondary analyses were also performed to
explore potential effects of gender on this association.
METHODS
Identiﬁcation of Relevant Studies and Samples
for Inclusion
Study selection procedure. Published studies examining the
association between SLC1A1 and OCD were originally identiﬁed
via the MEDLINE/PubMed database using the terms ‘‘OCD’’ and
‘‘SLC1A1,’’ with a focus on the 30 region of the gene. Additional
published studies were identiﬁed through examination of the
reference lists of the studies identiﬁed throughMEDLINE. Unpub-
lished datasets and raw genotype data for the pooled analysis were
sought by contacting the authors of the published studies.
Study inclusion/exclusion. Studies were included in the pooled
and/or meta-analyses if they had a type of control group (either
unrelated controls or parents) and an OCD group, if SNPs within
the 30 region of the SLC1A1 gene were examined and if the original
authors agreed to provide raw genotype data. Excluded studies
involved review articles and association studies that examined the
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relationship of SLC1A1 to non-OCD anxiety disorders. Data from
SLC1A1 SNPs in any published (or unpublished) linkage studies
were not included in analyses.
Rawdata extraction. Rawdata from individual studies thatwas
analyzed included phenotype information, SNP genotypes and
minor allele frequencies.
Quality control. In order to obtain the most accurate assess-
ment of data quality, the full datasets providedby the siteswere used
in the calculation of QC statistics. Genotype data from each site
were cleaned using an iterative quality control (QC) process,
whereby markers and subjects with excessive missing values
(>50%) were dropped before the next round of QC standards
were applied. In subsequent steps, SNPs were dropped for excessive
missing values (>10%), low minor allele frequencies (<5%),
high Mendel error rates (>5%), and apparent deviations from
Hardy–Weinberg equilibrium (P-value< 103). Subjects were re-
moved for excessive missing values (>10%) and for high Mendel
error rates (>5%). All QC steps were performed using PLINK
[Purcell et al., 2007] (http://pngu.mgh.harvard.edu/purcell/plink/)
for the pooled dataset. Additionally, QC checks were performed on
the merged ﬁnal dataset to ensure that Mendel error rates and
Hardy–Weinberg P-values remained within acceptable ranges.
Statistical Analyses
We ﬁrst conducted a pooled analysis of the family based data in
PLINK using the transmission disequilibrium test (TDT) [Purcell
et al., 2007]. We subsequently identiﬁed the common set of
genotyped SNPs between family-based studies and case–control
studies and then conducted single-marker analyses of these SNPs
using PLINK. For the pooled analysis of family-based data, we
conducted only single-marker association testing and did not
examine haplotypes.
We then performed a meta-analysis using weighted z-scores to
combine association results from the pooled family-based analysis
and the case–control analysis [see de Bakker et al., 2008, for a review
of themethod]. The z-score was calculated from the chi-square and
odds ratio test statistics provided in the PLINK output:
zi ¼
ﬃﬃﬃﬃﬃ
x21
q
for chi-square testes with 1 df ; z > 0
if odds ratio > 1; and z < 0 if odds ratio < 1
As the original studies included different groups of SNPs in their
analyses, the sample size for each SNP test in this study was
essentially unique. Thus, rather than weighting each original study
(as is typically done in a meta-analysis) this study weighted each
single-marker test. PLINK was used to obtain the number of
complete trios (sample size) genotyped for each SNP. The four
association tests performed in the case–control sample were given
the same weight, as there was only one case–control study.Weight-
ing was established using the Genetic Power Calculator [Purcell
et al., 2003]. This online tool was used to obtain the non-centrality
parameter (NCP) for each of these samples and to generate a
theoretical equivalent ‘‘effective’’ case–control study with a 1:1
case:control ratio. The theoretical case–control sample with the
NCP value closest to that of the actual sample was used to weight
each single-marker association test as follows:
Relative weight ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Ni
Ntotal
s
where Ni is the theoretical equivalent case–control sample size and
Ntotal is the sum of the theoretical sample sizes of the association
tests performed for that SNP, that is the sum of theoretical
equivalent weights of the family-based test and case–control test,
when a case–control association test had been performed for that
SNP.
The tests for the ﬁve SNPs genotyped exclusively in family-based
studies did not require weighting, as no case–control results were
available for meta-analysis. For the other four SNPs, weighted
z-scores were summed to produce overall meta-analysis z-scores.
Chi-square values were generated by squaring the z-scores from
the meta-analysis, and these chi-square values were then converted
into P-values based on the normal distribution with one-degree of
freedom. The results of the association tests for each of the nine
polymorphisms were indicated as z-scores, P-values, and odds
ratios with corresponding 95% conﬁdence intervals. Odds ratios
were calculated according to a ﬁxed-effects model [Trikalinos
et al., 2008]. To account for multiple testing of the nine examined
SNPs, Bonferroni correction was conducted, and the required
adjusted P-value was deﬁned at 0.0056.
RESULTS
Study-Sample Descriptions
Samples included in this analysis were incorporated from one
case–control study [Wendland et al., 2009] and four family-based
studies [Arnold et al., 2006; Dickel et al., 2006; Stewart et al., 2007a;
Shugart et al., 2009]. It should be noted that the sample from the
study by Samuels et al. [2011] was the same as that by Shugart et al.
[2009], but with genotyping of additional SNPs. Authors from each
of these ﬁve identiﬁed studies agreed to provide original raw
genotype data from their samples to enable the application of
uniform quality control (QC) ﬁlters for the purpose of this study.
Unpublished family-based data from theOCDMini-Collaborative,
which included samples from Boston, Ann Arbor (Michigan), San
Francisco and Toronto, were also entered into the analyses.
In each original study, case or proband status was deﬁned by the
presence of a current diagnosis of Obsessive-Compulsive Disorder
basedonDSM-III-RorDSM-IV (Diagnostic andStatisticalManual
of Mental Disorders), [American Psychiatric Association, 2000]
criteria which were assessed via established psychiatric interviews.
Subjects were recruited primarily fromOCD and anxiety clinics, as
described previously [Arnold et al., 2006;Dickel et al., 2006; Stewart
et al., 2007a; Shugart et al., 2009; Wendland et al., 2009]. Subjects
from these original cohorts were primarily Caucasian, although age
and, notably, age-of-onset were variable. Only one study [Shugart
et al., 2009] and the San Francisco site of the OCD Mini-Collabo-
rative excluded probands with comorbid Tourette disorder, a
common comorbidity estimated to occur in 10–30% of OCD cases
[Geller et al., 1996; Ivarsson et al., 2008; Langley et al., 2010].
Previously unanalyzed genotype data collected through the OCD
Mini-Collaborative were also included. After QC exclusions, the
OCD Mini-Collaborative sample contributed 170 new complete
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trios as well as 124 complete trios that had been previously included
in one of the original ﬁve family-based association studies.
Study-Sample Genotyping and Veriﬁcation
The platforms used for genotyping in the different published
studies included TaqMan (TaqMan; Applied Biosystems; Foster
City, California), Illumina GoldenGate and BeadArray system
(Illumina; San Diego, CA), and Sequenom hME (Sequenom;
MassARRAY; San Diego, CA). Genotyping performed by the
OCD Mini-Collaborative was conducted on the Sequenom iPLEX
platform (Sequenom; MassARRAY; San Diego, CA). In earlier
studies performed by Arnold et al. [2006] and Dickel et al.
[2006] the primary goal of SNP selection was to provide adequate
coverage of SLC1A1. Subsequent studies by Stewart et al., Shugart
et al., and Wendland et al. were designed, in part, to replicate the
positive associations reported by these earlier studies, such that the
majority of markers selected had been genotyped previously. In
addition, Shugart et al. included SNPs from outside of the SLC1A1
gene with potential regulatory properties, and Wendland et al.
included SNPs predicting gene expression levels.
Some of the original genotyping runs included assays unrelated
to SLC1A1 as well as subjects affected by disorders other thanOCD.
After QC exclusions were made, the datasets were reﬁned by
excluding all data related toOCD-unaffected families (from family-
based databases) and non-30 SLC1A1-related SNPs. Because the
QCthresholdsused in this studydiffered slightly from those applied
in the original studies, the post-QC datasets for meta-analysis
inclusion were not identical to datasets analyzed in the original
studies. To address this fact, attempts were made to replicate the
original results by analyzing our post-QC datasets according to
the methods—namely programs and settings—described in the
published papers [FBAT (http://www.biostat.harvard.edu/fbat/
default.htm), [Laird et al., 2000] PBAT (http://www.biostat.
harvard.edu/clange/default.htm), [Lange et al., 2004] and TDT
in Haploview (http://www.broadinstitute.org/haploview/haploview)
[Barrett et al., 2005]. For each published study, concordance
between original and new results was judged to be adequate (see
Supplementary Table I).
Meta-Analysis SNPs
Of the SNPs passing QC thresholds described above, 18 were
common to at least two of the published studies and/or the
unpublished OCD mini-collaborative data. The SNPs genotyped
in the ﬁve original studies are presented in Table I.Moreover, SNPs
that were included in the recently published OCD GWAS [Stewart
et al., 2012], and those included in a combined meta-analysis of
multiple OCD candidate genes [Taylor, 2012], are identiﬁed.
Genomic positions are those described in NCBI (National Center
for Biotechnology Information) Build 36dbSNP Build 131/UCSC
hg18hg19. Selection of SNPs for inclusion in this meta-analysis was
based on whether a signiﬁcant association, either as a single marker
or as part of a haplotype, had been reported previously for the SNP
and whether data were available from at least one additional study
sample. Accordingly, nine SNPs were analyzed for this study. Data
were coded in terms of forward strand orientation and thenmerged
(with the exception of the case–control data) in PLINK [Purcell
et al., 2007] using the default consensus calling setting. Among
studies whose participants were later re-genotyped by the OCD
Mini-Collaborative, overall concordance rates exceeded 99% in all
cases. Additionally, QC checks were performed on themerged ﬁnal
dataset to ensure that Mendel error rates and Hardy–Weinberg
P-values remained within the acceptable ranges.
The linkage disequilibrium (LD) pattern of the 9 SLC1A1 loci,
which span a 22.5 kb region, was established using genotype data
from individuals in thismeta-analysis. Haplotype constructionwas
performed in Haploview [Barrett et al., 2005]. The LD structure of
these 9 SNPs is illustrated in Figure 1.
Meta-Analysis of Family-Based and Case–Control
Single-Marker Associations
Four family-based association studies and one case–control study
were included in thismeta-analysis. Table II presents characteristics
for each of the ﬁve studies. The total sample size for this meta-
analysis included 815 complete trios and 306 cases with 634
ethnicity- and sex-matched controls. Males comprised 43.9% of
OCD-affected probands (N¼ 358) and 43.5% of cases (N¼ 133).
The original ﬁve studies had reported a combined total of
12 signiﬁcant single-marker associations between SLC1A1 poly-
morphisms and OCD. Among these SNPs, four were found to
be associated exclusively in males, and only one was found to
be associated in a global sample but not in the corresponding
male subsample (see Table I).
In the present meta-analysis, one of the nine examined SNPs
(rs301443) had a nominally signiﬁcant uncorrected P-value
(P¼ 0.046). This association did not survive Bonferroni correction
for nine independent tests (required Bonferroni adjusted
P< 0.0056) (see Table III).
Secondary Analyses by Gender Stratiﬁcation
After stratifying the family and case–control datasets by gender of
the affected proband, a secondary meta-analysis was performed on
the male subsample. Only rs12682807 had a nominally signiﬁcant
uncorrected P-value (P¼ 0.012). This association did not survive
multiple testing correction (see Table III).
DISCUSSION
To date, SLC1A1 has been considered the strongest biological
candidate gene for OCD based on positional linkage evidence
[Hanna et al., 2002; Willour et al., 2004a; Nicolini et al., 2009],
functional evidence connecting glutamate and OCD, and relatively
consistent genetic association ﬁndings across samples. No other
OCD candidate gene has demonstrated this level of supportive
evidence. In the absence of replication at the polymorphism level,
however, the association between SLC1A1 and OCD has not been
established. By integrating all relevant published and unpublished
data, this study was able to provide an overall estimate of effect size
for each of the nine SLC1A1 polymorphisms that had been signiﬁ-
cantly associated with OCD in at least one previous study, and for
whichdatawere available frommore thanone site.Althougheachof
these SNPs had demonstrated associationwith theOCDphenotype
STEWART ET AL. 371
TA
B
LE
I.
3
’S
LC
1
A1
Fi
n
di
n
gs
Fr
om
As
so
ci
at
io
n
,
G
W
AS
an
d
M
et
a-
An
al
ys
is
O
CD
St
u
di
es
3
’S
LC
1
A1
SN
Ps
in
ve
st
ig
at
ed
SN
Ps
O
ri
gi
n
al
st
ud
y
ﬁ
n
di
n
gs
in
cl
ud
ed
in
m
et
a-
an
al
ys
is
O
th
er
st
u
di
es
SN
P
H
G
1
8
po
si
ti
on
Ar
n
ol
d
et
al
.
D
ic
ke
l
et
al
.
St
ew
ar
t
et
al
.
Sh
ug
ar
t
et
al
.
W
en
dl
an
d
et
al
.
M
in
iC
ol
la
bo
ra
ti
ve
(u
n
pu
bl
is
h
ed
)
G
W
AS
Ta
y
lo
r
m
et
a-
an
al
y
si
s
rs
3
0
1
4
3
0
ch
r9
:4
5
6
6
6
8
0
x
H
m
P
¼
0
.0
0
3
H
pe
rm
P
¼
0
.0
0
4
3
;
H
m
pe
rm
P
¼
0
.0
3
3
x
H
P
¼
0
.0
4
;
H
m
P
¼
0
.0
3
;
E
x
x
x
rs
3
7
8
0
4
1
2
ch
r9
:4
5
6
2
4
8
0
x
Sm
co
rr
P
¼
0
.0
3
6
Sm
pe
rm
P
¼
0
.0
4
5
x
x
x
x
x
rs
3
0
8
7
8
7
9
ch
r9
:4
5
7
6
8
0
8
S
pe
rm
P
¼
0
.2
2
;
Sm
pe
rm
P
¼
0
.0
3
;
H
P
¼
0
.0
0
3
;
H
m
P
¼
0
.0
0
6
x
x
H
P
¼
0
.0
4
;
H
m
P
¼
0
.0
3
x
x
rs
3
0
1
4
3
4
ch
r9
:4
5
7
2
0
8
2
S
pe
rm
P
¼
0
.0
0
6
;
Sm
pe
rm
P
¼
0
.0
1
;
H
P
¼
0
.0
0
3
;
H
m
P
¼
0
.0
0
6
x
x
x
x
lo
st
in
Q
C
x
x
rs
3
0
1
9
7
9
ch
r9
:4
5
6
6
8
5
1
x
H
m
P
¼
0
.0
0
3
x
x
x
x
rs
3
0
1
4
3
5
ch
r9
:4
5
7
2
8
4
3
x
x
x
rs
3
0
1
4
4
3
ch
r9
:4
5
8
4
9
1
9
x
S
co
rr
P
¼
0
.0
1
7
x
rs
1
2
6
8
2
8
0
7
ch
r9
:4
5
6
4
0
2
2
H
pe
rm
P
¼
0
.0
0
4
3
;
H
m
pe
rm
P
¼
0
.0
3
3
x
rs
2
0
7
2
6
5
7
ch
r9
:4
5
6
6
4
5
1
H
pe
rm
P
¼
0
.0
0
4
3
;
H
m
pe
rm
P
¼
0
.0
3
3
x
x
rs
2
2
2
8
6
2
2
(f
or
m
er
ly
s7
8
5
6
2
0
9
)
ch
r9
:4
5
5
4
4
3
2
x
Sm
pe
rm
P
¼
0
.0
4
5
x
x
rs
7
8
5
8
8
1
9
ch
r9
:4
5
4
9
8
9
2
H
P
¼
0
.0
4
;
H
m
P
¼
0
.0
3
;
E
rs
3
9
3
3
3
3
1
ch
r9
:4
3
7
9
9
4
1
E
x
rs
1
9
8
0
9
4
3
ch
r9
:4
5
0
4
2
4
6
x
x
x
x
rs
3
7
8
0
4
1
5
ch
r9
:4
5
4
5
5
7
3
x
x
x
rs
1
0
9
7
4
6
2
5
ch
r9
:4
5
5
1
5
9
6
x
x
rs
1
0
8
1
4
9
8
7
ch
r9
:4
4
7
3
3
0
3
x
x
rs
1
0
7
3
9
0
6
2
ch
r9
:4
4
9
2
8
4
8
x
x
rs
1
0
1
1
5
6
0
0
ch
r9
:4
5
0
9
3
6
9
x
x
rs
3
7
8
0
4
1
3
ch
r9
:4
5
5
7
3
5
3
x
x
rs
3
0
1
4
4
0
ch
r9
:4
5
8
0
3
0
5
x
rs
3
0
1
4
3
7
ch
r9
:4
5
7
7
5
6
0
x
Si
n
gl
e
n
uc
le
ot
id
e
po
ly
m
or
ph
is
m
s
(S
N
Ps
)
lis
te
d
by
rs
#
in
cl
ud
e
th
os
e
ex
am
in
ed
in
pr
ev
io
us
O
CD
st
ud
ie
s
of
3
’S
LC
1
A1
.T
he
ba
se
pa
ir
lo
ca
ti
on
fo
r
ea
ch
SN
P
is
lis
te
d
in
th
e
co
lu
m
n
to
th
e
ri
gh
t
of
th
e
SN
P
co
lu
m
n
(H
G
1
8
Po
si
ti
on
).
Th
e
n
in
e
SN
Ps
in
cl
ud
ed
in
th
is
m
et
a-
an
al
ys
is
ar
e
lis
te
d
in
th
e
to
p
n
in
e
ro
w
s.
Fi
ve
co
lu
m
n
s
ar
e
pr
ov
id
ed
fo
r
pr
ev
io
us
ly
pu
bl
is
he
d
st
ud
y
ﬁ
n
di
n
gs
,o
n
e
is
pr
ov
id
ed
fo
r
pr
ev
io
us
ly
un
pu
b
lis
he
d
ﬁ
n
di
n
gs
,o
n
e
is
p
ro
vi
de
d
fo
r
a
pu
bl
is
he
d
G
W
AS
an
d
on
e
is
pr
ov
id
ed
fo
r
th
e
on
ly
ot
he
r
O
CD
ge
n
ot
y
p
e
m
et
a-
an
al
ys
is
.B
la
n
k
ce
lls
w
it
hi
n
ro
w
s
in
di
ca
te
th
e
ab
se
n
ce
of
th
at
SN
P
fr
om
th
e
re
la
te
d
st
ud
y.
Ce
lls
w
it
h
an
‘x
’i
n
di
ca
te
th
at
th
e
SN
P
w
as
ge
n
ot
yp
ed
bu
tt
ha
tt
he
P-
va
lu
e
w
as
>
0
.0
5
.C
el
ls
w
it
h
a
P-
va
lu
e
<
0
.0
5
ar
e
lis
te
d
ac
co
rd
in
g
to
th
e
ty
pe
of
re
la
te
d
as
so
ci
at
io
n
te
st
:S
,s
ig
n
iﬁ
ca
n
ts
in
gl
e
m
ar
ke
ra
ss
oc
ia
ti
on
;S
m
,s
ig
n
iﬁ
ca
n
ts
in
gl
e
m
ar
ke
ra
ss
oc
ia
ti
on
in
m
al
es
;H
,p
ar
to
fs
ig
n
iﬁ
ca
n
th
ap
lo
ty
pe
;H
m
,p
ar
to
fs
ig
n
iﬁ
ca
n
th
ap
lo
ty
pe
in
m
al
es
;c
or
r P
,s
ig
n
iﬁ
ca
n
ts
in
gl
e
m
ar
ke
ra
ss
oc
ia
ti
on
w
it
h
O
CD
af
te
rc
or
re
ct
io
n
fo
rm
ul
ti
pl
e
te
st
in
g;
pe
rm
P,
si
gn
iﬁ
ca
n
t
si
n
gl
e
m
ar
ke
r
as
so
ci
at
io
n
w
it
h
O
CD
af
te
r
pe
rm
ut
at
io
n
te
st
in
g;
E,
SL
C1
A1
eQ
TL
(e
xp
re
ss
io
n
qu
an
ti
ta
ti
ve
tr
ai
t
lo
cu
s)
.
372 AMERICAN JOURNAL OF MEDICAL GENETICS PART B
in one or more of the original studies, most of these associations
were no longer signiﬁcant when data were combined across
studies. This meta-analysis found only two nominally signiﬁcant
associations—rs301443 in the global sample (P¼ 0.046, ﬁxed-
effects pooled OR¼ 1.17) and rs12682807 in the male sample
(P¼ 0.012, ﬁxed-effects pooled OR¼ 1.65)—among the nine
examined SLC1A1 polymorphisms and OCD.
The greatest strength of this meta-analysis lies in its sample size.
It represents a signiﬁcant increase inpower as compared toprevious
studies. The smallest of the original SLC1A1 studies contained
66 families [Stewart et al., 2007a] and the largest contained
378 families [Shugart et al., 2009]. The combined sample for this
meta-analysis included 815 affected offspring trios and 306 cases
with 634 controls. Thus, power to detect an association was
markedly increased by combining these samples. The only compa-
rable study, a meta-analysis of polymorphisms from multiple
candidate genes in OCD [Taylor, 2012], included ﬁve of the
SLC1A1 polymorphisms that were examined by us but excluded
data from the large study by Shugart et al. [2009] and also excluded
rs3014443 (our major ﬁnding). Taylor reported a nominally
signiﬁcant association with the 30 SNP rs3087879, which was not
found in our meta-analysis.
Additionally, we were able to conduct a pooled analysis, as
authors of all ﬁve of the original studies generously agreed to
provide their original, pre-QC genotype data. Pooled analyses
produce similar results to meta-analyses [Lin and Zeng, 2010],
however they have the advantages of allowing for more consistent
quality control and facilitating secondary analyses [Lin and Zeng,
2010; Consortium, 2012]. The previouslymentionedmeta-analysis
by Taylor [2012] was limited by using only data reported in earlier
publications, thus necessitating exclusion of studies for which there
was insufﬁcient data to compute odds ratios.
Furthermore, our pooled analysis was generally robust against
potential bias from population stratiﬁcation because most of the
data were from family-based association studies. Lastly, all sites
contributing data to our study used well-validated phenotyping
methods based upon standard DSM criteria, decreasing the risk for
a dilution effect emerging from misdiagnosis and inappropriate
study inclusion.
A secondary analysis was conducted on males to test for a sex-
speciﬁc associationbetween SLC1A1 andOCD, given reports of this
in all but one of the original published studies, including all four
family-based association studies [Arnold et al., 2006; Dickel et al.,
2006; Stewart et al., 2007a; Shugart et al., 2009]. The majority of
reported single-marker associations in SLC1A1 were driven by
males, which is consistent with the sex differences observed in
phenotypic presentations of OCD. The course of the disorder is
more chronic in males [Ravizza et al., 1997; Bogetto et al., 1999],
who are also more likely to experience onset during childhood.
Males are alsomore likely topresentwith comorbid conditions such
as tic disorder or attention-deﬁcit/hyperactivity disorder [Fischer
et al., 1996; Lensi et al., 1996; Bogetto et al., 1999; Zohar et al., 1999;
FIG. 1. SLC1A1 SNPs included for meta-analysis and their previously reported single marker or haplotype OCD associations. Single marker
associations: SNP4–Dickel et al., 2006, Stewart et al., 2007; SNP9– Arnold et al., 2006; SNP11– Arnold et al., 2006; SNP12–Shugart et al., 2009.
Haplotype associations: SNPs 5, 6, 7 – Stewart et al., 2007; SNPs 7, 8 – Dickel et al., 2006; SNPs 7, 11 –Wendland et al., 2009; SNPs 9, 11 – Arnold
et al., 2006.
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Matsunaga et al., 2000; Tukel et al., 2004]. Segregationanalyses have
also revealed evidence of sexual dimorphism in the inheritance of
OCD [Nestadt et al., 2000a; Hanna et al., 2005a]. However, the
present meta-analysis provided limited evidence of a sex-speciﬁc
association between SLC1A1 and OCD. While the total combined
OCD-affected samplewas less than half (43.8%)male, resulting in a
signiﬁcant reduction in power for the secondary analysis, thismeta-
analysis is nevertheless the most comprehensive exploration of sex
effects on the SLC1A1-OCD association to date.
The largely negative results of this meta-analysis are not entirely
unexpected, given the ﬁndings from previous individual studies.
Only three of the nine markers included in this meta-analysis were
reported to be signiﬁcant, either as a single marker or as part of a
haplotype, in more than one of the previous studies. The only SNP
that had been positively associated with SLC1A1 as a single marker
in more than one study was rs3780412, and this SNP was not
signiﬁcant in either the global or male-speciﬁc analysis of the
present meta-analysis. This study does not, therefore, clarify the
ﬁndings from previous association studies involving SLC1A1 and
OCD. The lack of association suggests that previous ﬁndings may
have been false positive results. However, other limitations of this
study may also explain the lack of an association in this meta-
analysis. First, despite the relatively large sample size compared to
earlier, single site studies, this meta-analysis is admittedly small
relative to current guidelines for study size. The Psychiatric GWAS
Consortium Coordinating Committee [2009] reported that the
majority of recent signiﬁcant association ﬁndings involve alleles
with genotypic relative risks of 1.1–1.4, and that detection of such
risk alleles may require samples of between 8,000 and 20,000 cases
[Cichon et al., 2009].
Second, heterogeneity at both the genetic and phenotypic level
may have impeded our ability to detect an association. Sample size
considerations are especially relevant in light of the genetic hetero-
geneity thought to underlie OCD [Liang et al., 2008]. For example,
while the ﬁrst linkage scan for OCD [Hanna et al., 2002; Willour
et al., 2004b] reported a linkage signal on chromosome 9p24 that
was subsequently replicated [Willour et al., 2004a], subsequent
linkage studies using primarily sibling pairs [Shugart et al., 2006a;
Hanna et al., 2007; Ross et al., 2011; Mathews et al., 2012] failed to
detect this signal. Furthermore, in the linkage study byWillour et al.
[2004a] the group noted that only 59% of their pedigrees had
demonstrated evidence for linkage with the 9p24 candidate region.
Linkage studies are robust to allelic heterogeneity [Risch, 2000] but
not to locus heterogeneity, and both forms of heterogeneity will
contribute to poor replication across association studies.
Marked heterogeneity of the OCD phenotype has also been
consistently identiﬁed as a formidable challenge in genetic studies
of the disorder. The present meta-analysis combined early-onset
OCD cases with adult-onset OCD cases, despite the assertion that
genetic etiology of early-onset OCDmay be distinct [Walitza et al.,
2010]. In a large family study of OCD, Nestadt et al. [2000b] found
that earlier age at onset was strongly associated with familiality
and saw no evidence of familiality when age at onset was older than
17 years. Additionally, a meta-analysis of twin studies in OCD
performed by van Grootheest et al. [2005] found dramatically
higher heritability in the early-onset form of the disorder, from
0.45 to 0.65, whereas heritability in adult-onset cases ranged from
TA
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0.27 to 0.47. The results of this meta-analysis also suggest the
potential importance of subphenotypic considerations for future
genetic studies of OCD. Factor analytic studies have repeatedly
demonstrated that OCD is comprised of discrete but overlapping
symptom dimensions [Mataix-Cols et al., 2005; Stewart et al.,
2007b; Stewart et al., 2008]. It has been proposed that speciﬁc
symptom dimensions may be more closely tied to underlying
genetic etiologic factors than the entire phenotypic spectrum of
the disorder, such that different candidate genesmay be responsible
for phenotypic expression of distinct symptom dimensions [Pato
et al., 2002]. Ideally, a meta-analysis of OCD would stratify by
symptomdimensions for secondary analyses. However, the present
study would not have been adequately powered to detect SLC1A1
association with putative age-of-onset or symptom-based OCD
subphenotypes [Wendland et al., 2009; Samuels et al., 2011].
In addition to the sample size andheterogeneity, a thirdpotential
limitation of this study is the particular analytic method selected.
Numerous analytic approaches exist for combining case–control
and family-based data [Infante-Rivard et al., 2009], including
extensions of likelihood models and combinations of distinct
estimates. For the latter category, which was employed in this
meta-analysis, two separate analyses were ﬁrst performed; using
a chi-square test in the case–control dataset and a TDT in the
merged trio dataset. Kazeem and Farrall [2005] described the
method of integrating case–control and TDT studies using odds
ratios, which canbeweighted since the logarithmof the odds ratio is
asymptotically normally distributed. Nicodemus [2008] described
some of the computational packages designed to carry out such
analyses, but for the current meta-analysis we determined that the
easiest and most reliable method of combining the estimates of
disease-marker association was the weighted z-score, as described
by deBakker et al. [2008]. The z-score can be easily derived from the
chi-square and odds ratio, both of which were provided in the
PLINK output. Because the odds ratio was not provided in the
FBAT output, PLINK was a much more attractive program than
FBAT for analyzing the family-based data. While this study
employed a standardized approach across all analyses, a different
approach could have been used, which may have altered the results
slightly. This slight lack of precision is particularly relevant to the
present study, in which markers are demonstrating only modest
association to the disease phenotype.
Finally, the current meta-analysis of SLC1A1 is premised on
potentially incorrect assumptions about its underlying genetic
architecture. We examined only common polymorphisms, when
it may be the case that multiple rare variants within SLC1A1
contribute to the OCD phenotype. Detecting such rare variants
would require a sequencing approach.Todate, studies searching for
rare variation in SLC1A1 [Veenstra-VanderWeele et al., 2001, 2012;
Wang et al., 2010] have been limited in scope to coding regions and
have primarily used capillary-based screeningmethods, rather than
targeting the entire gene via next-generation sequencing methods.
Also, if there is substantial allelic heterogeneity for SLC1A1 and
OCD, haplotype [Lambert et al., 2012] or gene-based [Huang et al.,
2011; Bacanu, 2012] analytic methods that consider combined
effects of SNPs may be more likely to identify associations. Finally,
it is possible that insertion/deletion or copy number variants were
contributors to the previously identiﬁed OCD associations with
SLC1A1. It is interesting in this regard that our strongest ﬁndings
was for rs301443, which lies within a small deletion detected by
Dickel et al. [2006].
In conclusion, the glutamate transporter geneSLC1A1has been a
very promising candidate gene forOCD, supported by various lines
of biological evidence in addition to multiple genetic association
studies. However, this meta-analysis does not support a strong role
for common SLC1A1 risk variants in OCD etiology, nor does it
convincingly establish a role for gender in the overall OCD risk
liability ofSLC1A1polymorphisms.On theotherhand, it is possible
that the signals observed in this analysis are legitimate and represent
a true association between SLC1A1 and OCD. Regardless, it is
important to note that the results do not undermine the potential
contribution of glutamatergic dysregulation to OCD pathology.
Investigating the roles of glutamatergic systems in OCD remains
warranted and is relevant to both clinical practice and future
research. The results from this study demonstrate the need for
larger collaborative samples and subphenotyping, and highlight the
potential for false-positive ﬁndings, or at least the need for cautious
interpretation of positive ﬁndings, with candidate gene studies. If
heterogeneity of the SLC1A1 gene comprises both common and
rare variants, then next-generation sequencing may also be pro-
ductive in future studies of SLC1A1 and OCD [Wang et al., 2010;
Bailey et al., 2011].
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